FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. SPY
2. TSLA
3. META
4. HOOD
5. STZ
6. INTC
7. SPCX
8. GOOGL
9. FDS
10. FUTU

Go back to FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

RBC Capital on Biogen (BIIB): 'CMS Makes It Clear - Leqembi Will Be Broadly Reimbursed - Should Reduce Overhang'

April 26, 2023 3:16 PM EDT

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $340.00 price target on Biogen (NASDAQ: BIIB).

The analyst comments "We believe many people have been on the sidelines on BIIB because of concerns around Leqembi events this year - upcoming competitor data from LLY, an AdComm, the PDUFA for potential full approval, and CMS decision on reimbursement. Our sense has been that reimbursement is the biggest uncertainty weighing on the stock and on perceptions around Leqembi's long-term potential, as despite CMS's contention they will broaden reimbursement as soon as the drug... More